Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

1268 results about "Mammalian cell" patented technology

Mammalian cells show a large diversity in shape and are both shape-changing and mobile when cultured on conventional uniform substrates. The use of micropatterning techniques limits the number of variable parameters, by imposing shape and standardized adhesive areas on the cells, which facilitates analysis.

Base editors and uses thereof

Some aspects of this disclosure provide strategies, systems, reagents, methods, and kits that are useful for the targeted editing of nucleic acids, including editing a single site within the genome of a cell or subject, e.g., within the human genome. The disclosure provides fusion proteins of nucleic acid programmable DNA binding proteins (napDNAbp), e.g., Cas9 or variants thereof, and nucleic acid editing proteins such as cytidine deaminase domains (e.g., novel cytidine deaminases generated by ancestral sequence reconstruction), and adenosine deaminases that deaminate adenine in DNA. Aspects of the disclosure relate to fusion proteins (e.g., base editors) that have improved expression and / or localize efficiently to the nucleus. In some embodiments, base editors are codon optimized for expression in mammalian cells. In some embodiments, base editors include multiple nuclear localization sequences (e.g., bipartite NLSs), e.g., at least two NLSs. In some embodiments, methods for targeted nucleic acid editing are provided.
Owner:THE BROAD INST INC

Modified ligand-gated ion channels and methods of use

ActiveUS12247064B2Cell membraneLigand-gated ion channel
This document relates to materials and methods for modulating ligand gated ion channel (LGIC) activity. For example, modified LGICs including at least one LGIC subunit having a modified ligand binding domain (LBD) and / or a modified ion pore domain (IPD) are provided. Also provided are exogenous LGIC ligands that can bind to and activate the modified LGIC, as well as methods of modulating ion transport across the membrane of a cell of a mammal, methods of modulating the excitability of a cell in a mammal, and methods of treating a mammal having a channelopathy.
Owner:HOWARD HUGHES MEDICAL INST

Anti-CD3 nano antibody capable of activating T cell activity as well as preparation method and application of anti-CD3 nano antibody

The invention belongs to the field of molecular biology and immunology, and particularly relates to an anti-CD3 nano antibody capable of activating the activity of T cells as well as a preparation method and application of the anti-CD3 nano antibody. The invention provides a preparation method of the anti-CD3 nano antibody. The preparation method comprises the following steps: constructing a CD3 plasmid and an overexpression cell line, and immunizing alpaca to obtain peripheral blood mononuclear cells (PBMC) of the alpaca; extracting RNA (Ribonucleic Acid) and carrying out reverse transcription to obtain cDNA; carrying out PCR amplification on the antibody gene segment and cloning the antibody gene segment to a phage display vector; and electrically transforming the vector into SS320 competent cells to obtain the nano antibody library. After two rounds of panning, detecting and screening an antibody clone capable of being combined with the CD3 protein through ELISA (Enzyme-Linked Immunosorbent Assay); an antibody sequence is selected through sequencing, and an antibody protein is expressed by using a mammalian cell high-throughput expression system; and then detecting and screening the antibody which is only specifically combined with the CD3. The method disclosed by the invention is simple, convenient and rapid to operate, and can be used for preparing active antibodies for treating potential tumors and proliferative diseases.
Owner:BIOINTRON BIOLOGICAL INC

Stabilized formulations of lipid nanoparticles

The disclosure features a lipid nanoparticle (LNP) formulation comprising a plurality of LNPs and a stabilizing agent that mitigates the degradation of the LNPs or a subpopulation thereof. Lipid nanoparticles further including therapeutics and / or prophylactics such as RNA are useful in the delivery of therapeutics and / or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression. Methods of manufacturing LNP formulations and screening for a stabilizing agent are also disclosed.
Owner:MODERNATX INC

Compounds and compositions for intracellular delivery of therapeutic agents

The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions further including therapeutic and / or prophylactics such as RNA are useful in the delivery of therapeutic and / or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.
Owner:MODERNATX INC

Algal co-culture system

Mammalian cell production systems are disclosed herein wherein a living mammalian cell culture including a mammalian growth medium operative is co-cultured with a living algae cell culture including an algae growth medium operative to feed nutrients and carbon dioxide to a plurality of algae cells and to transport an algae waste from the plurality of algae cells. The living algae cell culture produces an algae waste with one or more nutrients and oxygen operative to feed the mammalian cell culture, while the living mammalian cell culture produces a mammalian waste with one or more nutrients and carbon dioxide operative to feed the algae cell culture. The systems are capable of a continuous operation at normal mammalian temperature and pH, thereby removing a need to cool down the algae growth medium and / or heat up the algae growth medium for a treatment of algae or for a replenishment of algae.
Owner:BOSTON COLLEGE +1

Mammalian cell expression vector, expression plasmid and expression system

The invention discloses a mammalian cell expression vector, an expression plasmid and an expression system. The expression vector sequentially comprises the following elements: (a) a promoter; (b) a Kozak sequence; (c) a polyadenine sequence, the polyadenine sequence sequentially comprises a bGH PolyA sequence and a 5 'UTR PolyA sequence, the nucleotide sequence of the bGH PolyA sequence is as shown in SEQ ID NO.5, and the nucleotide sequence of the 5' UTR PolyA sequence is as shown in SEQ ID NO.6; (d) copying the start site; and (e) screening marker genes. According to the present invention, the expression vector is optimized by the expression element, such that the exogenous gene can be conveniently, efficiently and flexibly inserted and edited by the expression vector so as to achieve the stable extracellular or intracellular expression of the exogenous protein, and the expression efficiency of the exogenous protein can be improved by carrying out the expression plasmid construction based on the expression vector; and more efficient expression and purification of the foreign protein are realized.
Owner:INST OF HEALTH & MEDICINE HEFEI COMPREHENSIVE NAT SCI CENT

Plasmin degradation product D-dimer antibody and application thereof

The invention relates to a biotechnology, and particularly discloses a plasmin degradation product D-dimer antibody and application thereof. According to the application, a single B cell antibody preparation technology and a flow cytometry sorting method are applied to the development of a blood coagulation in-vitro diagnosis fibrinolysis system detection antibody for the first time, and a mammalian cell expression system (293F) is adopted to successfully express and obtain three strains of D-dimer monoclonal antibodies (antibody numbers are DD-1, DD-2 and DD-3) with biological activity. Compared with the on-sale Roch D-dimer antibody, the three antibodies have the same affinity with the DD antigen, and can identify and detect the D-dimer in plasma with high specificity and high sensitivity; meanwhile, the probe has no cross reaction with fibrinogen, primary fibrinolytic substances (X, Y and D) and soluble fibrin (SF), and can be used for qualitative or quantitative detection of D-dimer.
Owner:BEIJING SICCEEDER TECH CO LTD

Anti-human CD3 rabbit recombinant monoclonal antibody as well as preparation method and application thereof

The invention relates to the technical field of biological medicines, and particularly discloses an anti-human CD3 rabbit recombinant monoclonal antibody as well as a preparation method and application thereof. The antibody obtains anti-CD3 immune response by immunizing a rabbit, is obtained by combining single B cell sorting, gene cloning and a mammalian cell expression system, and has high affinity and good specificity. The antibody can effectively recognize CD3 positive T cells in human peripheral blood and can be applied to the fields of flow cytometry, immunohistochemistry, T cell function research and the like. Experimental results show that the antibody has the advantages of high titer, strong fluorescence signal, low background and the like, and is superior to the traditional murine anti-CD3 antibody. Amino acid sequences of light chain and heavy chain variable regions of the antibody are further obtained, and controllability and repeatability of antibody expression are achieved. The antibody has important scientific research value and industrial application prospect, and is suitable for various scenes such as T cell marker detection, immune state evaluation, immunotherapy auxiliary research and the like.
Owner:JIANGSU ATAS BIOTECHNOLOGY CO LTD

Iscb mutein and use thereof

PCT designated stage expiredWO2025138738A1HydrolasesForeign genetic material cellsBiotechnologyArginine
The present invention belongs to the technical field of bioengineering. Provided are an IscB mutein and the use thereof. Compared to the wild-type IscB protein, the IscB mutein comprises arginine at at least one of the following amino acid positions: position 84, position 96, position 102, position 111, position 159, position 368 and position 386; preferably, the IscB mutein further comprises arginine at position 401 and position 456. The relatively strong interaction between the IscB mutein and a double-stranded DNA target improves the editing activity for mammalian cell lines, which can greatly enhance the application potential of the IscB mutein as a new-generation underlying tool for gene editing, and promote the use of the IscB mutein in the aspects of precision medicine, animal model construction and crop breeding.
Owner:EAST CHINA NORMAL UNIV +1

Compounds that participate in cooperative binding and uses thereof

The invention features compounds (e.g., macrocyclic compounds) capable of modulating biological processes, for example through binding to a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein (e.g., a eukaryotic target protein such as a mammalian target protein or a fungal target protein or a prokaryotic target protein such as a bacterial target protein). These compounds bind endogenous intracellular presenter proteins, such as the FKBPs or cyclophilins, and the resulting binary complexes selectively bind and modulate the activity of intracellular target proteins. Formation of a tripartite complex among the presenter protein, the compound, and the target protein is driven by both protein-compound and protein-protein interactions, and both are required for modulation of the targeted protein's activity. In some embodiments, the compounds of the invention “re-program” the binding of the presenter proteins to protein targets that either do not normally bind to the presenter protein (e.g., do not show detectable binding in mammalian cells absent the compound). In some embodiments, provided compounds “re-program” presenter protein binding to greatly enhance interaction with a particular target with which it may have some interaction absent the compound. Interactions achieved through such reprogramming result in an ability to modulate the activity of these new targets.
Owner:REVOLUTION MEDICINES INC

Base editors and uses thereof

Some aspects of this disclosure provide strategies, systems, reagents, methods, and kits that are useful for the targeted editing of nucleic acids, including editing a single site within the genome of a cell or subject, e.g., within the human genome. The disclosure provides fusion proteins of nucleic acid programmable DNA binding proteins (napDNAbp), e.g., Cas9 or variants thereof, and nucleic acid editing proteins such as cytidine deaminase domains (e.g., novel cytidine deaminases generated by ancestral sequence reconstruction), and adenosine deaminases that deaminate adenine in DNA. Aspects of the disclosure relate to fusion proteins (e.g., base editors) that have improved expression and / or localize efficiently to the nucleus. In some embodiments, base editors are codon optimized for expression in mammalian cells. In some embodiments, base editors include multiple nuclear localization sequences (e.g., bipartite NLSs), e.g., at least two NLSs. In some embodiments, methods for targeted nucleic acid editing are provided.
Owner:THE BROAD INST INC

Synthetic self-amplifying mRNA molecules with secretory antigens and immunomodulators

Lipid nanoparticles (LNPs) encapsulating self-amplifying mRNA, compositions, and methods of use of the novel nucleic acid constructs and compositions are disclosed. The LNP constructs comprise a novel ionizable lipid. The novel sa-mRNA constructs encode a modified SARS-CoV-2 spike protein in which the polynucleotide has been truncated to comprise no nucleotides encoding SARS-CoV-2 transmembrane domain and short cytoplasmic domain amino acids, as well as immunomodulators. The sa-mRNA may be used as a therapeutic, diagnostic and / or prophylactic agent for mammalian cells or organs.
Owner:SUNVAX MRNA THERAPEUTICS INC

Triple-hole paper-based cell three-dimensional culture chip as well as preparation method and application thereof

The invention relates to a triple-hole paper-based three-dimensional cell culture chip as well as a preparation method and application thereof. The chip comprises a paraffin hydrophobic region and a paper-based hydrophilic region. The preparation method mainly comprises the following steps: 1) designing a mask plate; 2) cutting the mask plate by laser; and 3) preparing the triple-hole paper-based chip by hot pressing. The thickness of the chip is 100-200 [mu] m, the porous fiber structure of the paper-based material allows transportation of oxygen and waste, and a three-dimensional microenvironment for in-vivo cell growth can be simulated. Meanwhile, a transparent and liquid-tight supporting layer is fused on the lower layer of the paper-based chip, so that leakage of cells inoculated on the upper layer of the paper-based chip is avoided. The paper-based chip is embedded into a 6-pore plate, and bladder cancer cells (5637), mouse astrocytoma (U87) and human breast cancer cells (MCF-7) are inoculated in a paper-based hydrophilic region respectively. The cell compatibility of the paper-based chip and the growth behaviors of three different types of cells in three-dimensional paper fibers are investigated. It is proved that the chip can be used for researching three-dimensional construction and growth of human and mammalian cells, and the difference between three-dimensional culture and two-dimensional culture is revealed by detecting the proliferation capacity and survival rate of different cells.
Owner:DALIAN UNIV OF TECH +1

Recombinant human III-type collagen as well as preparation method and application thereof

The invention provides recombinant human III-type collagen as well as a preparation method and application thereof, and belongs to the technical field of protein engineering, the amino acid sequence of the recombinant human III-type collagen is shown as SEQ ID No.1, and the nucleotide sequence of a gene for coding the recombinant human III-type collagen is shown as SEQ ID No.2; the invention also provides a method for expressing the recombinant human III type collagen in mammalian cells. The recombinant human III-type collagen provided by the invention is high in purity, has triple helix characteristic circular dichroism, has the molecular weight of 21.8 kDa, is far smaller than that of natural full-length collagen, has the effects of promoting cell proliferation and cell migration, and reduces obstacles for the collagen to penetrate through a skin barrier to exert biological functions.
Owner:SHENZHEN LIYING BIOTECHNOLOGY CO LTD +1

Compositions and methods for delivery of nucleic acids to cells

PCT designated stage expiredWO2024236361A1Organic active ingredientsMetabolism disorderSterolNanoparticle
The disclosure features novel lipid nanoparticle formulations and use thereof. Lipid nanoparticles include cationic ionizable lipids, helper lipids, sterols, and conjugated lipids. Lipid nanoparticles further including therapeutics and / or prophylactics such as DNA are useful in the delivery of therapeutics and / or prophylactics to cells or organs (e.g., mammalian cells or organs) to, for example, regulate polypeptide, protein, or gene expression.
Owner:TAKEDA PHARMA CO LTD

Cas9 nuclease and application thereof

The invention belongs to the technical field of biology, and provides Cas9 nuclease, a CRISPR / Cas system comprising the Cas9 nuclease and application of the CRISPR / Cas system, and the Cas9 nuclease has an amino acid sequence as shown in SEQ ID NO: 1. The invention also provides a related nucleic acid, an expression vector comprising the nucleic acid and a recombinant cell. The genome editing activity of the Cas9 nuclease in mammalian cells is verified, and the Cas9 nuclease provides more tools and effective site selections for the in-vivo gene editing application direction.
Owner:SHENZHEN HUADA GENE INST

Method for generating multivalent and multispecific antibody-expressing cells by targeted integration of multiple expression cassettes in a defined tissue format

Reported herein is, inter alia, a method for producing a trivalent bispecific antibody, the method comprising the steps of culturing a mammalian cell comprising a deoxyribonucleic acid encoding the trivalent bispecific antibody, and recovering the trivalent bispecific antibody from the cell or culture medium, wherein the deoxyribonucleic acid encoding the trivalent bispecific antibody is stably integrated into the genome of the mammalian cell and comprises in the 5' to 3' direction a first expression cassette encoding a first heavy chain, a second expression cassette encoding the first heavy chain, a third expression cassette encoding a first light chain, a fourth expression cassette encoding the first light chain, a fifth expression cassette encoding the second heavy chain, a sixth expression cassette encoding the first light chain or the second heavy chain or the second light chain, and a seventh expression cassette encoding the second light chain, wherein the first heavy chain The chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain, a CH3 domain, a peptide linker, a second heavy chain variable domain and a CL domain, the second heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain and a CH3 domain, the first light chain comprises, from N-terminus to C-terminus, a first light chain variable domain and a CH1 domain, and the second light chain comprises, from N-terminus to C-terminus, a second light chain variable domain and a CL domain, wherein the second heavy chain variable domain and the first light chain variable domain form a first binding site, and the first heavy chain variable domain and the second light chain variable domain form a second binding site.
Owner:F HOFFMANN LA ROCHE & CO AG

Recombinant humanized anti-Cpn IgM monoclonal antibody as well as preparation method and application thereof

The invention relates to the technical fields of gene engineering, antibody engineering and immunodiagnosis. The invention provides a recombinant humanized anti-Cpn IgM monoclonal antibody. The monoclonal antibody comprises a light chain variable region and a heavy chain variable region, the light chain variable region comprises three complementary determining regions CDR1, CDR2 and CDR3, and the amino acid sequences of the three complementary determining regions are respectively shown as SEQ ID NO.3, SEQ ID NO.4 and SEQ ID NO.5; the heavy chain variable region comprises three complementary determining regions CDR1, CDR2 and CDR3, and the amino acid sequences of the three complementary determining regions are shown as SEQ ID NO.6, SEQ ID NO.7 and SEQ ID NO.8 respectively. The invention also provides a method for preparing the monoclonal antibody. The recombinant humanized anti-Cpn IgM monoclonal antibody provided by the invention is expressed in mammalian cells by utilizing a gene recombination technology, has the characteristics of high purity, small batch difference and the like, and can be applied to a Cpn IgM antibody detection kit as a quality control product; as a quality control product, the recombinant humanized anti-Cpn IgM monoclonal antibody has the advantages of high sensitivity, high safety, inter-batch stability and the like.
Owner:QINGDAO SHUOJING BIOTECHNOLOGY CO LTD

Application of bifidobacterium breve i1088 or afterbiogen of bifidobacterium breve i1088 to improvement of cognition

PendingCN119587588Aimprove cognitive functionIncrease the number of timesMilk preparationNervous disorderBiotechnologyDisease
The invention relates to an application of bifidobacterium breve i1088 or a postbiotic thereof in improvement of cognition. The bifidobacterium breve i1088 or the afterbiogen of the bifidobacterium breve i1088 is used for preparing a product for enhancing the oxidative stress capacity of mammalian cells, improving the in-vitro free radical scavenging level of mammals and changing at least one of the expression levels of mammalian cells Nrf2 and anti-oxidation related genes. The invention aims to explore the potential of the bifidobacterium breve in the aspect of improving the Alzheimer's disease and provide a safer and more effective nutritional supplement scheme for middle-aged and elderly people.
Owner:JUNLEBAO DAIRY GRP CO LTD

Ultra-small-volume gene editing system and application thereof in construction of cell factory

PendingCN118995669AEfficiently implement knockoutHydrolasesStable introduction of DNABiotechnologyEscherichia coli
The invention provides an ultra-small-volume gene editing system based on TnpB protein derived from Campylobacter coli and application of the ultra-small-volume gene editing system in construction of a cell factory. The ultra-small-volume gene editing system can be used for carrying out genetic operations such as efficient knockout, insertion and continuous editing on target genes in escherichia coli and mammalian cells. The invention provides a more convenient and efficient gene editing tool for the research fields of metabolic engineering transformation, gene therapy and the like.
Owner:ZHEJIANG UNIV OF TECH

Biotin ligase mutant, coding gene thereof, expression vector, recombinant cell and application of biotin ligase mutant

The invention belongs to the technical field of gene engineering, and particularly relates to a biotin ligase mutant as well as a coding gene, an expression vector, a recombinant cell and application thereof. The amino acid sequence of the biotin ligase mutant is as shown in SEQ ID NO. 2. The biotin ligase (Bar A) mutant provided by the invention can be efficiently expressed in eukaryotes, the expression level of the biotin ligase (Bar A) mutant is obviously improved in mammalian cells compared with a wild type, and the biotin ligase (Bar A) mutant has good catalytic activity after expression, can effectively catalyze biotinylation of protein containing a biotin receptor sequence, and has good application prospects. The method has a wide application prospect in the fields of biotinylated protein preparation, and protein labeling, positioning, immunodetection, affinity purification, function research and the like based on a biotin-avidin system (BAS).
Owner:YOURUISAISI (WUHAN) BIOTECHNOLOGY CO LTD

Controllable expression in mammalian cells

This invention provides a nucleic acid construct comprising; (i) a first nucleotide sequence for expression, (ii) a first promoter operably linked to the first nucleotide sequence, said first promoter being inducible, (iii) a first insulating sequence located upstream of the first nucleotide sequence and first promoter, (iv) a second insulating sequence located downstream of the first nucleotide sequence and first promoter, (v) a second nucleotide sequence encoding a transcription regulator protein that induces expression from the first promoter; and (vi) a second promoter operably linked to the second nucleotide sequence. The second nucleotide sequence and second promoter may be located either (a) upstream of the first insulating sequence or (b) downstream of the second insulating sequence. Also provided are vectors and mammalian cells comprising the construct, methods of inducibly expressing a nucleotide sequence in the construct, and methods of producing a mammalian cell by inducing expression from the construct.
Owner:CAMBRIDGE ENTERPRISE LTD

Cas12 protein and use thereof

PCT designated stage expiredWO2025021168A1HydrolasesMicroencapsulation basedBase JMammalian cell
A Cas12 protein and a use thereof. The amino acid sequence of the Cas12 protein comprises or is a sequence having at least 50% sequence identity to SEQ ID NO: 1, and the amino acid sequence of the Cas12 protein comprises or is a sequence different from SEQ ID NO: 1 in amino acids at one, two or more positions. The amino acid sequence of the Cas12 protein comprises or is an amino acid sequence having at least 50% identity to SEQ ID NO: 18, and a PAM sequence identified by the Cas12 protein is A. By carrying out rational and non-rational mutation on the amino acid sequence of a natural Cas12 protein, the gene editing efficiency of the natural Cas12 protein in mammalian cells is improved. The Cas12 protein achieves higher editing efficiency and / or a lower off-target rate, and the PAM sequence is a single A base, so that many target sequences which are previously difficult to edit can be edited, thereby greatly expanding the editing range.
Owner:GUANGZHOU REFORGENE MEDICINE CO LTD +2

Tat47-57 binding analogue based on decafluorobiphenyl as well as preparation method and application of Tat47-57 binding analogue

The invention discloses a decafluorobiphenyl-based Tat47-57 binding peptide, the amino acid sequence of the binding peptide is shown as SEQ ID NO.1 or SEQ ID NO.2, the fourth amino acid and the eighth amino acid of the SEQ ID NO.1 are bound through decafluorobiphenyl, and the fifth amino acid and the twelfth amino acid of the SEQ ID NO.2 are bound through decafluorobiphenyl. In particular, the decafluorobiphenyl-based Tat47-57 binding peptides (P3 and P6) are efficient CPPs, capable of delivering a variety of cargo molecules into the cytoplasm of mammalian cells. Meanwhile, decafluorobiphenyl cyclization plays a key role in cellular uptake and endosome escape. The two peptides P3 and P6 show remarkable cell permeability, and are speculated to enter cells through gridding protein dependent endocytosis. They also show efficient endosome escape ability, and have successfully applied P3 and P6 as CPPs to deliver phospholipid peptides and avidin.
Owner:LANZHOU UNIV

A method for preparing a universal all-pig monoclonal antibody

The present invention belongs to the technical field of monoclonal antibody preparation, and specifically relates to a method for preparing a universal whole-pig monoclonal antibody. The present invention is based on single B cell antibody preparation technology, and antigen-specific single B lymphocytes are separated from the peripheral blood of immune pigs or clinically recovered pigs by flow cytometry sorting technology; according to the pig immunoglobulin IgG antibody gene sequence in the database, primers are designed to specifically amplify the complete coding genes of antibody heavy and light chains in pig single B cells and add His tags, and pCDNA3.1-Leader is used as a eukaryotic expression vector to construct a recombinant vector of complete coding genes for antibody light and heavy chains, and natural whole-pig monoclonal antibodies are expressed by mammalian cells. The present invention establishes a universal whole-pig monoclonal antibody preparation method for the first time, which can be used for the preparation and screening of pig monoclonal antibody libraries of different pathogens. Compared with other antibody preparation methods, it has the advantages of high throughput, whole pig source, good diversity, complete antibodies and natural pairing, etc., which provides technical support for the rapid preparation and screening of pig monoclonal antibodies and has broad application prospects.
Owner:CHINA INST OF VETERINARY DRUG CONTROL

Cryopreservation formulations

The disclosure provides for cryopreservation formulations, cryopreservation media and method of cryopreserving mammalian cells or tissues. The cryopreservation formulations and media contain a combination of cryoprotective agents selected from the group consisting of; (a) glycerol and trehalose; (b) glycerol, trehalose, and ascorbic acid; (c) glycerol, trehalose, and taurine: and (d) glycerol, trehalose, ascorbic acid, and taurine. In certain embodiments, the cryopreservation formulations and media are free of dimethyl sulfoxide.
Owner:COLOSSAL BIOSCIENCES INC

Screening method for signal peptides for efficient expression and secretion of heterologous polypeptides in mammalian cells - Patents.com

The present disclosure is directed to a method for screening signal peptides for efficient expression and secretion of heterologous polypeptides in mammalian cells, comprising: providing a pool of viral expression vectors encoding a polypeptide of interest comprising a variety of candidate signal peptides, wherein each viral expression vector of the pool comprises at least a polynucleotide encoding a fusion protein, the polynucleotide comprising: (i) a promoter, (ii) a sequence encoding a signal peptide, (iii) a sequence encoding a polypeptide of interest, (iv) optionally, a sequence encoding an epitope tag, and (v) a sequence encoding a C-terminal signal peptide for glycosylphosphatidylinositol (GPI) attachment or a sequence encoding a transmembrane domain; hosting the viral vector pool such that each host cell is preferably transformed with only one viral vector from the pool on average. The method includes the steps of transforming a host cell; expressing the fusion protein in the host cell to produce a fusion protein that is anchored to the host cell surface by a GPI or a transmembrane domain of the fusion protein; contacting the host cell with a first binding reagent, preferably an antibody that specifically binds to the target polypeptide; or, if an epitope tag is present in the fusion protein, a first binding reagent that specifically binds to the epitope tag; contacting the host cell with the first binding reagent, which may optionally be labeled with a fluorescent label or other detection means; dividing the transformed host cells into at least two groups based on the fluorescent properties of each host cell; and performing next-generation sequencing on the group of host cells that show the most efficient fusion protein expression to identify the optimal signal peptide for the target polypeptide in the host cell. The present disclosure is also directed to the vector, host cell, or DNA library used in the method.
Owner:ヘルシンギン イリオピスト

Soluble fibrin (SF) antibodies and uses thereof

The invention relates to a biotechnology, and particularly discloses a soluble fibrous protein (SF) antibody and an application of the soluble fibrous protein antibody. According to the present invention, the single B cell antibody preparation technology and the flow cytometry sorting method are firstly applied to the blood coagulation in vitro diagnosis fibrinolysis system detection antibody development, and the mammalian cell expression system (293F) is adopted to successfully express and obtain the three strains of the SF monoclonal antibodies (the antibody numbers are SF-1, SF-2 and SF-3) with the biological activity; the three antibodies have specific reactions with SF, have no cross reactions with primary fibrinolytic substances (X, Y and D), can be applied to the fields of SF indirect ELISA and Western blotting detection and screening, make up the vacancy of domestic SF antibodies in the market, and realize fibrinolytic system detection integrity.
Owner:BEIJING SICCEEDER TECH CO LTD